Literature DB >> 23532296

[First stage of the cross-cultural adaptation of the instrument The Vulnerable Elders Survey (VES-13) to Portuguese].

Laércio Lima Luz1, Lívia Maria Santiago, João Francisco Santos da Silva, Inês Echenique Mattos.   

Abstract

The aim of this study was to describe the initial stages of the cross-cultural adaptation of the instrument The Vulnerable Elders Survey (VES-13) for use in the context of cancer care in Brazil. Two translations into Portuguese and two back-translations into English were carried out independently, and a formal assessment of the general and referential meanings was performed in order to obtain a synthesis version. Understanding of the synthesis version was evaluated in a pretest applied to 33 patients in an oncologic hospital of the Brazilian Unified National Health System (SUS). The version was easily applied in the intended context and was well-accepted by elders. The Portuguese version of the VES-13 proved to be well understood and adequate for testing its psychometric qualities. The latter step is currently in the final phase.

Entities:  

Mesh:

Year:  2013        PMID: 23532296     DOI: 10.1590/s0102-311x2013000300019

Source DB:  PubMed          Journal:  Cad Saude Publica        ISSN: 0102-311X            Impact factor:   1.632


  2 in total

Review 1.  Cross-cultural adaptation and measurement properties of generic and cancer-related patient-reported outcome measures (PROMs) for use with cancer patients in Brazil: a systematic review.

Authors:  Carlos Augusto Albach; Richard Wagland; Katherine J Hunt
Journal:  Qual Life Res       Date:  2017-09-08       Impact factor: 4.147

2.  Association of health vulnerability with adverse outcomes in older people with COVID-19: a prospective cohort study.

Authors:  Fábio Cavalcante de Assis; Michelle Cristina-Oliveira da Silva; João Carlos Geber-Júnior; Hamilton Roschel; Tiago Peçanha; Luciano Ferreira Drager; Alfredo Nicodemos Cruz Santana
Journal:  Clinics (Sao Paulo)       Date:  2021-12-06       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.